Abstract Details

Title Titration dosing of aducanumab: Results of a 12-month interim analysis from a randomized, double-blind, placebo-controlled Phase 1b study (PRIME) in patients with prodromal or mild Alzheimer's Disease

Topic Aging and Dementia

Presentation(s) S7 - (-)

Poster/Presentation
Number 003

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Vissia Viglietta, MD PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Tianle Chen, PhD	Dr. Chen has received personal compensation for serving as an employee of Biogen.
Ahmed Enayetallah, PhD, MBBCh (BlueRock Therapeutics)	Dr. Enayetallah has received personal compensation for serving as an employee of Alexion. Dr. Enayetallah has received stock or an ownership interest from Alexion. Dr. Enayetallah has received stock or an ownership interest from AstraZeneca.
Ping Chiao, MD (Biogen Idec)	No disclosure on file
	No disclosure on file
Roger Nitsch, MD (University of Zurich, Division of Psychiatry)	No disclosure on file
Samantha Budd Haeberlein	Samantha Budd Haeberlein has received personal compensation for serving as an employee of Biogen. An immediate family member of Samantha Budd Haeberlein has received personal compensation for serving as an employee of Alkermes. Samantha Budd Haeberlein has received stock or an ownership interest from Biogen.
Alfred W. Sandrock, MD, PhD (Biogen)	No disclosure on file